Searched for
TRANSDERMAL PRODUCTS
Aurobindo Pharma’s Raleigh plant gets 'Voluntary Action Indicated' classification from US FDAAurobindo Pharma's US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufa...- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...
- Most Trusted Brands to watch in 2024
- Rusan Pharma opens new API facility in Pithampur with Rs 300 crore investmentMumbai-based drug manufacturer Rusan Pharma has inaugurated a new active pharmaceutical ingredient (API) facility in Pithampur, Madhya Prad...
- Parineeti Chopra turns entrepreneur with strategic investment in ClenstaClensta offers a range of health and personal care products in the wellness, hair care, skincare, eye care, lip care and body-care categori...
- Buy Aurobindo Pharma, target price Rs 1100: Motilal OswalAurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 54796.98 Crore) operating in Pharma...
- US generics business to continue its growth momentum: Pharma firm Cadila HealthcareAccording to the Cadila Healthcare's annual report for fiscal year 2019-20, the company is planning to introduce additional "topical, trans...
- DRL jumps 3% after launching chest pain patchIt is one of the few stocks that have gained in 2020 and is up 34 per cent year-to-date.
- Cadila Healthcare gains on USFDA nod for memory loss drugThe group now has 252 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
- Aurobindo Pharma to launch oncology, respiratory products in US by 2021The company is also focussing on securing intellectual property (IP) and ramping up and filing of specialty products.
- Local pharma formulators to benefit from new USFDA generic guidance: ReportThis will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend repor...
- Rusan Pharma launches R&D centre, special manufacturing unit in GujaratFounded in 1994, the company is engaged in de-addiction and pain management products in the domestic and international markets.
- Rusan Pharma launches R&D centre, special manufacturing unit in GujaratRusan Pharma today launched a Rs 100 crore-R&D centre and specialised manufacturing unit for transdermal patches at Kandla Special Economic...
- Dr Reddy's acquires Habitrol brandDr Reddy's Laboratories has acquired Habitrol brand, a nicotine replacement therapy transdermal patch, from Novartis Consumer Health Inc.
- Dr Reddy's, Zydus, Cadila seek more time for their SEZ unitsMajor pharmaceutical firms have sought more time as they have not been able to obtain the necessary regulatory approvals in time.
- Elder Pharma to foray into anti-smoking segmentIndian drug maker Elder Pharmaceuticals plans to enter the nicotine replacement therapy, or anti-smoking segment, with chewable jelly cubes...
- 3M in talks to license drug delivery techUS-Based $23-billion diversified technology firm 3M is in talks with top domestic pharma companies to licence drug delivery technologies.
- Ranbaxy to market second licensed generic in CanadaThe generic fentanyl patch is sold under Ranbaxy's label 'Ran Fentanyl Transdermal System', used for management of persistent and chronic p...
Load More
